Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 11.36 is 15% above its 1-year average of 9.85, near the high end of its 1-year range (8.33–11.36).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly quick ratio; no daily interpolation.
Limited quarterly history available
Quick Ratio needs at least three reported quarters before a meaningful chart is shown.
QUICK RATIO (ACID-TEST)
11.36
QUICK RATIO (ACID-TEST) AVG TTM
N/A
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 870 covered companies
CURRENT VS SECTOR MEDIAN
+238.63%
vs the sector median at left
Odyssey Therapeutics, Inc.
Market Cap
$870.81M
Quick Ratio (Acid-Test)
11.36
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$867.03M
Quick Ratio (Acid-Test)
7.55
TTM Avg
6.94
3Y Avg
6.93
5Y Avg
8.87
Market Cap
$857.16M
Quick Ratio (Acid-Test)
0.76
TTM Avg
0.79
3Y Avg
0.88
5Y Avg
1.73
Market Cap
$884.97M
Quick Ratio (Acid-Test)
81.42
TTM Avg
11.94
3Y Avg
8.59
5Y Avg
10.34
Market Cap
$887.50M
Quick Ratio (Acid-Test)
1.17
TTM Avg
1.03
3Y Avg
0.92
5Y Avg
1.05
Market Cap
$887.99M
Quick Ratio (Acid-Test)
16.16
TTM Avg
3.88
3Y Avg
3.97
5Y Avg
4.50
Market Cap
$853.13M
Quick Ratio (Acid-Test)
1.79
TTM Avg
2.17
3Y Avg
1.93
5Y Avg
2.04
Market Cap
$852.35M
Quick Ratio (Acid-Test)
3.05
TTM Avg
34.00
3Y Avg
26.34
5Y Avg
26.34
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $870.81M | 11.36 | N/A | N/A | N/A |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | 7.55 | 6.94 | 6.93 | 8.87 |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | 0.76 | 0.79 | 0.88 | 1.73 |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | 81.42 | 11.94 | 8.59 | 10.34 |
| Alumis Inc. (ALMS)vs › | $855.38M | 6.74 | 5.17 | 5.15 | 5.15 |
| Bioventus Inc. (BVS)vs › | $887.50M | 1.17 | 1.03 | 0.92 | 1.05 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | 16.16 | 3.88 | 3.97 | 4.50 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 1.79 | 2.17 | 1.93 | 2.04 |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | 3.05 | 34.00 | 26.34 | 26.34 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | 4.03 | 6.29 | 5.71 | 7.79 |
Quick Ratio
11.36
Excludes inventory
Current Ratio
11.36
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 11.36 |
| 2026-03-31 | 8.33 |
